Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 3, 2019

Aevi reports negative results from Phase II ASCEND trial

Aevi Genomic Medicine has reported negative results from the Phase II AEVI-001-ADHD-202 (ASCEND) trial after it failed to meet the primary endpoint of the study.

Aevi Genomic Medicine has reported negative results from the Phase II AEVI-001-ADHD-202 (ASCEND) trial after it failed to meet the primary endpoint of the study.

The dose-optimisation, parallel-group study evaluated AEVI-001 in children aged six to 17 with attention deficit hyperactivity disorder (ADHD) with or without an mGluR copy number variant.

Primary endpoints of the trial included the reduction of ADHD-RS in the patients following six weeks of treatment with AEVI-001.

Results showed that AEVI-001 was safe and well tolerated with minimal adverse events reported among patients in both treatment groups.

Aevi Genomic Medicine CEO Michael Cola said: “We are very disappointed that the ASCEND trial did not achieve its primary endpoint.

“We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options.”

“We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“We will continue to focus on our pipeline of additional molecules, including AEVI-002 for severe pediatric-onset Crohn’s Disease and AEVI-005 for an undisclosed autoimmune orphan disease, both partnered with Kyowa Hakko Kirin.”

Aevi investigated orally-administered 100mg-400mg of AEVI-001 as part of the ASCEND trial.

The genomically-guided, double-blind, placebo-controlled study was conducted in two parts.

Part A of the trial included 69 subjects who have one of eight specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Part B enrolled 109 subjects who did not have copy number variants (CNVs) in any of the specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Both groups saw subjects randomised in 1:1 ratio to receive either AEVI-001 or placebo.

After being treated with the titrated dose of up to 400mg of AEVI-001, the participants entered a maintenance phase with weekly follow-up for up to six weeks.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU